Skip to Main Content

Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short.

Last Thursday in JAMA Oncology, Northwest Biotherapeutics and its scientific collaborators published the results of a large clinical trial showing its personalized cancer vaccine administered to patients with brain tumors reduced the risk of death by 20% compared to a group of patients taken from “external controls.” The same study results were presented Sunday at a neuro-oncology research meeting, as they were last May.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment